TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07741045: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease

Sponsor: Hangzhou PhecdaMed Co., Ltd. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,702,360

Rescue Site Savings

+$10,358,048

Unlock Full NCT07741045 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07741045 Rescue Dossier →